Rouan Sarah Kathryn 4
4 · Viking Therapeutics, Inc. · Filed Jan 19, 2024
Insider Transaction Report
Form 4
Rouan Sarah Kathryn
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-01-19$8.32/sh+30,000$249,600→ 30,000 total - Sale
Common Stock, par value $0.00001 per share
2024-01-19$23.05/sh−30,000$691,500→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-19−30,000→ 25,000 totalExercise: $8.32From: 2020-07-01Exp: 2029-07-01→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023.